Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Gains from Investment Securities: 2019-2025

Historic Gains from Investment Securities for Summit Therapeutics (SMMT) over the last 3 years, with Sep 2025 value amounting to $856,000.

  • Summit Therapeutics' Gains from Investment Securities was N/A to $856,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year change of. This contributed to the annual value of $4.2 million for FY2024, which is 0.68% down from last year.
  • Per Summit Therapeutics' latest filing, its Gains from Investment Securities stood at $856,000 for Q3 2025, which was down 62.01% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' Gains from Investment Securities registered a high of $4.2 million during Q2 2023, and its lowest value of $104,000 during Q4 2022.
  • Over the past 3 years, Summit Therapeutics' median Gains from Investment Securities value was $2.3 million (recorded in 2025), while the average stood at $2.6 million.
  • As far as peak fluctuations go, Summit Therapeutics' Gains from Investment Securities skyrocketed by 126,600.00% in 2021, and later tumbled by 91.78% in 2022.
  • Over the past 5 years, Summit Therapeutics' Gains from Investment Securities (Quarterly) stood at $1.3 million in 2021, then slumped by 91.78% to $104,000 in 2022, then reached $4.2 million in 2023, then reached $4.2 million in 2024, then crashed by 66.34% to $856,000 in 2025.
  • Its Gains from Investment Securities was $856,000 in Q3 2025, compared to $2.3 million in Q2 2025 and $1.4 million in Q1 2025.